Eli Lilly agreed to license clazakizumab, an IL‑6 monoclonal antibody from CSL, paying $100 million up front to expand its inflammation portfolio. CSL retained rights to pursue clazakizumab for prevention of cardiovascular events in end‑stage kidney disease while Lilly will explore the antibody across other indications. The deal reflects ongoing industry interest in IL‑6 biology and a race to broaden anti‑inflammatory pipelines. CSL will remain involved in select indications and stands to receive milestone and royalty payments; Lilly gains a late‑stage program to complement its immunology and obesity franchises. Observers noted Lilly’s recent acquisition and licensing activity signals a targeted push into inflammation and immune modulation, leveraging its commercial footprint to pursue multiple therapeutic opportunities.